A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

MLA

Hirsch FR, et al. “A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated with Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology, vol. 29, no. 26, Sept. 2011, pp. 3567–73. EBSCOhost, https://doi.org/10.1200/JCO.2010.34.4929.

APA

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR, Hirsch, F. R., Kabbinavar, F., Eisen, T., Martins, R., & Schnell, F. M. (2011). A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. Journal of Clinical Oncology, 29(26), 3567–3573. https://doi.org/10.1200/JCO.2010.34.4929

Chicago

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, et al. 2011. “A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated with Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology 29 (26): 3567–73. doi:10.1200/JCO.2010.34.4929.